Physician profile
Amory Mumbauer
NPI 1184901563
$3,910.77
in general payments reported to CMS, 2019-2025
33 companies · $790 in 2025
The $790 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $553 · 2023: $978 · 2024: $939 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $825.13 | 2021-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $815.17 | 2021-2025 | Relistor, Xifaxan |
| Abbvie INC. | $444.67 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $176.98 | 2021-2023 | Ztlido |
| Vertos Medical, INC. | $162.09 | 2022-2024 | Mild Device Kit |
| Amgen INC. | $160.30 | 2021-2022 | |
| Pfizer INC. | $158.91 | 2021-2025 | |
| Mml US, INC. | $151.10 | 2023 | Reactiv8 |
| Lilly USA, LLC | $149.07 | 2022-2024 | Mounjaro, Emgality, Zepbound |
| Almatica Pharma LLC | $105.29 | 2021-2023 | Gralise |
| Biodelivery Sciences International, INC. | $99.08 | 2021 | |
| Valinor Pharma, LLC | $69.22 | 2023-2025 | Movantik |
| Biohaven Pharmaceuticals, INC. | $67.73 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $58.36 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $56.06 | 2023-2024 | Austedo Xr, Austedo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $49.47 | 2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.33 | 2022 | |
| Alnylam Pharmaceuticals INC. | $33.91 | 2023 | Givlaari |
| Redhill Biopharma INC. | $25.05 | 2021 | |
| Halozyme INC | $24.84 | 2023 | |
| Foundation Fusion Solutions, LLC | $24.08 | 2024 | |
| Novo Nordisk INC | $21.57 | 2025 | Wegovy |
| Forte Bio-Pharma LLC | $19.99 | 2021 | |
| Antares Pharma, INC. | $19.56 | 2025 | Xyosted |
| Hikma Pharmaceuticals USA | $19.35 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $18.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.86 | 2023 | Seglentis |
| Nalu Medical, INC. | $17.43 | 2023 | Nalu Neurostimulation System |
| Electronic Waveform Lab, INC. | $15.89 | 2025 | |
| Horizon Therapeutics Plc | $15.58 | 2022 | |
| International Rehabilitative Sciences, INC | $14.74 | 2025 | Rs-4i Plus With Intersperse |
| Pacira Pharmaceuticals Incorporated | $13.35 | 2022 | |
| Medtronic, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amory Mumbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.